Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 18;9(2):460.
doi: 10.3390/cells9020460.

Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets

Affiliations
Review

Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets

Fabrizio Fontana et al. Cells. .

Abstract

Prostate cancer (PCa) represents a major cause of cancer mortality among men in developed countries. Patients with recurrent disease initially respond to androgen-deprivation therapy, but the tumor eventually progresses into castration-resistant PCa; in this condition, tumor cells acquire the ability to escape cell death and develop resistance to current therapies. Thus, new therapeutic approaches for PCa management are urgently needed. In this setting, natural products have been extensively studied for their anti-PCa activities, such as tumor growth suppression, cell death induction, and inhibition of metastasis and angiogenesis. Additionally, numerous studies have shown that phytochemicals can specifically target the androgen receptor (AR) signaling, as well as the PCa stem cells (PCSCs). Interestingly, many clinical trials have been conducted to test the efficacy of nutraceuticals in human subjects, and they have partially confirmed the promising results obtained in vitro and in preclinical models. This article summarizes the anti-cancer mechanisms and therapeutic potentials of different natural compounds in the context of PCa prevention and treatment.

Keywords: chemoprevention; natural compounds; novel therapeutic strategies; phytochemicals; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of the major anti-prostate cancer (PCa) phytochemicals.
Figure 2
Figure 2
Mechanisms of action and molecular targets of phytochemicals in PCa.

Similar articles

Cited by

References

    1. Fitzmaurice C., Allen C., Barber R.M., Barregard L., Bhutta Z.A., Brenner H., Dicker D.J., Chimed-Orchir O., Dandona R., Dandona L., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. JAMA Oncol. 2017;3:524. - PMC - PubMed
    1. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco F.J., Jr., Dotan Z.A., Fearn P.A., Kattan M.W. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl. Cancer Inst. 2006;98:715–717. doi: 10.1093/jnci/djj190. - DOI - PMC - PubMed
    1. Perlmutter M.A., Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 2007;9:S3–S8. - PMC - PubMed
    1. Thomas T.S., Pachynski R.K. Treatment of advanced prostate cancer. Mo. Med. 2018;115:156–161. - PMC - PubMed
    1. Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M., Wong Y.N., Hahn N., Kohli M., Cooney M.M., et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl. J. Med. 2015;373:737–746. doi: 10.1056/NEJMoa1503747. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances